Literature DB >> 27017186

Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.

Constance Manso1, Luis Querol2, Mourad Mekaouche1, Isabel Illa2, Jérôme J Devaux3.   

Abstract

Paranodal axoglial junctions formed by the association of contactin-1, contactin-associated protein 1, and neurofascin-155, play important functions in nerve impulse propagation along myelinated axons. Autoantibodies to contactin-1 and neurofascin-155 define chronic inflammatory demyelinating polyradiculoneuropathy subsets of patients with specific clinical features. These autoantibodies are mostly of the IgG4 isotype, but their pathogenicity has not been proven. Here, we investigated the mechanisms how IgG subclasses to contactin-1 affect conduction. We show that purified anti-contactin-1 IgG1 and IgG4 bind to paranodes. To determine whether these isotypes can pass the paranodal barrier, we incubated isolated sciatic nerves with the purified antibody or performed intraneural injections. We found that IgG4 diffused into the paranodal regions in vitro or after intraneural injections. IgG4 infiltration was slow and progressive. In 24 h, IgG4 accessed the paranode borders near the nodal lumen, and completely fill the paranodal segments by 3 days. By contrast, control IgG, anti-contactin-1 IgG1, or even anti-contactin-associated-protein-2 IgG4 did not pass the paranodal barrier. To determine whether chronic exposure to these antibodies is pathogenic, we passively transferred anti-contactin-1 IgG1 and IgG4 into Lewis rats immunized with P2 peptide. IgG4 to contactin-1, but not IgG1, induced progressive clinical deteriorations combined with gait ataxia. No demyelination, axonal degeneration, or immune infiltration were observed. Instead, these animals presented a selective loss of the paranodal specialization in motor neurons characterized by the disappearance of the contactin-associated protein 1/contactin-1/neurofascin-155 complex at paranodes. Paranode destruction did not affect nodal specialization, but resulted in a moderate node lengthening. The sensory nerves and dorsal root ganglion were not affected in these animals. Electrophysiological examination further supported these results and revealed strong nerve activity loss affecting predominantly small diameter or slow conducting motor axons. These deficits partly matched with those found in patients: proximal motor involvement, gait ataxia, and a demyelinating neuropathy that showed early axonal features. The animal model thus seemed to replicate the early deteriorations in these patients and pointed out that paranodal loss in mature fibres results in conduction defects, but not conduction slowing. Our findings indicate that IgG4 directed against contactin-1 are pathogenic and are reliable biomarkers of a specific subset of chronic inflammatory demyelinating polyneuropathy patients. These antibodies appear to loosen the paranodal barrier, thereby favouring antibody progression and causing paranodal collapse.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CIDP; autoantibody; caspr; dysimmune; neuritis

Mesh:

Substances:

Year:  2016        PMID: 27017186     DOI: 10.1093/brain/aww062

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  34 in total

1.  From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases.

Authors:  Chong Xie; Ze Wang; Nan Zhao; Desheng Zhu; Xiajun Zhou; Jie Ding; Yifan Wu; Haojun Yu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-15       Impact factor: 3.307

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

3.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

4.  Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Authors:  Constance Manso; Luis Querol; Cinta Lleixà; Mallory Poncelet; Mourad Mekaouche; Jean-Michel Vallat; Isabel Illa; Jérôme J Devaux
Journal:  J Clin Invest       Date:  2019-03-14       Impact factor: 14.808

5.  Distal Acquired Demyelinating Symmetric Neuropathy Associated with Decreased Electrical Excitability of the Femoral Nerves.

Authors:  Vasily I Khodulev; Vladimir V Ponomarev; Julia I Stepanova
Journal:  Maedica (Bucur)       Date:  2021-12

Review 6.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

7.  Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.

Authors:  Kristina R Patterson; Josep Dalmau; Eric Lancaster
Journal:  Ann Neurol       Date:  2018-01-10       Impact factor: 10.422

Review 8.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

Review 9.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 10.  Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.

Authors:  Jun-Ichi Kira
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.